STOCK TITAN
  1. Home
  2. Sec-filings
  3. MRNA
  4. [ARS] Moderna, Inc. SEC Filing

[ARS] Moderna, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
ARS

Rhea-AI Filing Summary

Analyzing...
ARS - Moderna, Inc.

ARS Filing - Moderna, Inc.

This filing is available as a PDF document.

Filing Type: ARS

Company: Moderna, Inc. (MRNA)

Acceptance Date: 2026-03-16T16:31:08.000Z

View PDF Document

Source: View Original Filing on SEC EDGAR

Moderna

NASDAQ:MRNA

View MRNA Stock Overview →

MRNA Rankings

#586 Ranked by Market Cap
N/A Ranked by Dividends

MRNA Latest News

Mar 3, 2026
Moderna Resolves Global Patent Litigation with Arbutus/Genevant
Feb 27, 2026
European Medicines Agency's Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19
Feb 19, 2026
Moderna to Present at Upcoming Conferences in March 2026
Feb 18, 2026
Moderna Announces the U.S. Food and Drug Administration will Initiate the Review of Its Investigational Seasonal Influenza Vaccine Submission
Feb 17, 2026
Moderna Receives European Commission Marketing Authorization for COVID-19 Vaccine mNEXSPIKE

MRNA Latest SEC Filings

Mar 16, 2026
[DEF 14A] Moderna, Inc. Definitive Proxy Statement
Mar 6, 2026
[Form 4] Moderna, Inc. Insider Trading Activity
Mar 6, 2026
[Form 4] Moderna, Inc. Insider Trading Activity
Mar 4, 2026
[8-K] Moderna, Inc. Reports Material Event
Mar 3, 2026
[Form 4] Moderna, Inc. Insider Trading Activity

MRNA Stock Data

20.76B
365.94M
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
United States
CAMBRIDGE